Furthermore, Tsao et al. established the prognostic significance of CCL11 in NSCLC, revealing that lower pretreatment serum CCL11 levels correlate with reduced progression-free survival in vandetanib-treated patients, suggesting its potential as a predictive biomarker [65]. This evidence concerns the gene CCL11 and non-small cell lung carcinoma.